This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, P. C. Articles by Libutti, S. K. Search for Related Content PubMed PubMed Citation Articles by Wu, P. C. Articles by Libutti, S. K.

In Vivo Sensitivity of Human Melanoma to Tumor Necrosis Factor (TNF)- Is Determined by Tumor Production of the Novel Cytokine Endothelial-Monocyte Activating Polypeptide II (EMAPII)

Surgical Metabolism Section, Surgery Branch, National Cancer Institute [P. C. W., H. R. A., J. H., P. H., M. G., A. C. B., E. T., S. K. L.], and Hematology Section, Clinical Pathology, Clinical Center [O. W.], NIH, Bethesda, Maryland 20892

Tumor necrosis factor (TNF)- is a potent anticancer agent that seems to selectively target tumor-associated vasculature resulting in hemorrhagic necrosis of tumors without injury to surrounding tissues. The major limitation in the clinical use of TNF has been severe dose-limiting toxicity when administered systemically. However, when administered in isolated organ perfusion it results in regression of advanced bulky tumors. A better understanding of the mechanisms of TNF-induced antitumor effects may provide valuable information into how its clinical use in cancer treatment may be expanded. We describe here that the release of a novel tumor-derived cytokine endothelial-monocyte-activating polypeptide II (EMAPII) renders the tumor-associated vasculature sensitive to TNF. EMAPII has the unique ability to induce tissue factor production by tumor vascular endothelial cells that initiates thrombogenic cascades, which may play a role in determining tumor sensitivity to TNF. We demonstrate here that constituitive overexpression of EMAPII in a TNF-resistant human melanoma line by retroviral-mediated transfer of EMAPII cDNA renders the tumor sensitive to the effects of systemic TNF in vivo, but not in vitro. This interaction between tumors and their associated neovasculature provides an explanation for the focal effects of TNF on tumors and possibly for the variable sensitivity of tumors to bioactive agents.

This article has been cited by other articles:

				L. Crippa, A. Gasparri, A. Sacchi, E. Ferrero, F. Curnis, and A. Corti Synergistic Damage of Tumor Vessels with Ultra Low-Dose Endothelial-Monocyte Activating Polypeptide-II and Neovasculature-Targeted Tumor Necrosis Factor-{alpha} Cancer Res., February 15, 2008; 68(4): 1154 - 1161. [Abstract] [Full Text] [PDF]

				A. Slominski, D. J. Tobin, S. Shibahara, and J. Wortsman Melanin Pigmentation in Mammalian Skin and Its Hormonal Regulation Physiol Rev, October 1, 2004; 84(4): 1155 - 1228. [Abstract] [Full Text] [PDF]

				R. Clarijs, L. Schalkwijk, D. J. Ruiter, and R. M. W. de Waal EMAP-II Expression Is Associated with Macrophage Accumulation in Primary Uveal Melanoma Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 1801 - 1806. [Abstract] [Full Text] [PDF]

				S. Matschurat, U. E. Knies, V. Person, L. Fink, B. Stoelcker, C. Ebenebe, H. A. Behrensdorf, J. Schaper, and M. Clauss Regulation of EMAP II by Hypoxia Am. J. Pathol., January 1, 2003; 162(1): 93 - 103. [Abstract] [Full Text] [PDF]

				J. Friedl, M. Puhlmann, D. L. Bartlett, S. K. Libutti, E. N. Turner, M. F. X. Gnant, and H. R. Alexander Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF Blood, July 30, 2002; 100(4): 1334 - 1339. [Abstract] [Full Text] [PDF]

				S. Y. Chang, S. G. Park, S. Kim, and C.-Y. Kang Interaction of the C-terminal Domain of p43 and the alpha Subunit of ATP Synthase. ITS FUNCTIONAL IMPLICATION IN ENDOTHELIAL CELL PROLIFERATION J. Biol. Chem., March 1, 2002; 277(10): 8388 - 8394. [Abstract] [Full Text] [PDF]

				M. Zheng, M. A. Schwarz, S. Lee, U. Kumaraguru, and B. T. Rouse Control of Stromal Keratitis by Inhibition of Neovascularization Am. J. Pathol., September 1, 2001; 159(3): 1021 - 1029. [Abstract] [Full Text] [PDF]

				M. F. X. Gnant, A. C. Berger, J. Huang, M. Puhlmann, P. C. Wu, M. J. Merino, D. L. Bartlett, H. Richard Alexander, and S. K. Libutti Sensitization of Tumor Necrosis Factor {{alpha}}-resistant Human Melanoma by Tumor-specific in Vivo Transfer of the Gene Encoding Endothelial Monocyte-activating Polypeptide II Using Recombinant Vaccinia Virus Cancer Res., September 1, 1999; 59(18): 4668 - 4674. [Abstract] [Full Text] [PDF]

				F. R. Zhang and M. A. Schwarz Pro-EMAP II is not primarily cleaved by caspase-3 and -7 Am J Physiol Lung Cell Mol Physiol, June 1, 2002; 282(6): L1239 - L1244. [Abstract] [Full Text] [PDF]